Dual incretin agonist: difference between revisions
Diff·revision 12 → 13·08:37, 18 Dec 2024
Difference between revision 12 and revision 13 of Dual incretin agonist. 6 lines changed; the page grew by 124 bytes.
| Revision 12 — 07:03, 30 Nov 2024 IncretinIvo (talk) add the molecular formula to the infobox 4,447 bytes +982 | Revision 13 — 08:37, 18 Dec 2024 TrialsTabitha (talk) correct the molar mass — source gives the free-base figure, we had the salt 4,571 bytes +124 | ||
|---|---|---|---|
| 36 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). PMID 34170647.</ref> | 36 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). PMID 34170647.</ref> |
| 37 | 37 | ||
| + | 38 | == See also == | |
| + | 39 | * [[Tirzepatide]] | |
| + | 40 | * [[Retatrutide]] | |
| + | 41 | * [[Triple agonist]] | |
| + | 42 | * [[Glucose-dependent insulinotropic polypeptide]] | |
| + | 43 | ||
| 38 | {{DEFAULTSORT:Dual incretin agonist}} | 44 | {{DEFAULTSORT:Dual incretin agonist}} |
| 39 | [[Category:Dual and triple agonists]] | 45 | [[Category:Dual and triple agonists]] |